Ipso Ventures Share Discussion Threads

[olly2] 24/6/2011 10:49

dropped the bid a little...

[5hakey] 24/6/2011 10:47

Can not buy online

[philmar089] 24/6/2011 10:23

3.70 sell 3.94 buy

[5hakey] 24/6/2011 10:19

Can not buy any online any one with same problem???

[olly2] 24/6/2011 09:51

they are now.........

[pre] 24/6/2011 09:43

careful!!....mm's not increasing bid...typical...

[topinfo] 24/6/2011 09:37

1 pence only last week though!!

[5harold] 24/6/2011 09:30

Just noticed a year ago IPS was raising cash by issuing shares at 10p each. Worth a punt in view of small cap ? Any views ?

[philmar089] 24/6/2011 08:50

Holding(s) in Company
Share this article

TIDMIPS

RNS Number : 0351J

Ipso Ventures PLC

24 June 2011

IPSO Ventures plc

HOLDING(S) IN COMPANY


TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i)
------------------------------------------------------------------------------

1. Identity of the issuer or the IPSO Ventures plc
underlying issuer of existing shares
to which voting rights are attached:
(ii)
--------------------------------------- -------------------------------------
2 Reason for the notification (please tick the appropriate
box or boxes):
------------------------------------------------------------------------------
An acquisition or disposal of voting rights: X
---------------------------------------------------------------- ------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition of
shares already issued to which voting rights are attached:
---------------------------------------------------------------- ------------
An acquisition or disposal of instruments with similar
economic effect to qualifying financial instruments:
---------------------------------------------------------------- ------------
An event changing the breakdown of voting rights:
---------------------------------------------------------------- ------------
Other (please
specify):
------------------ -------------------------------------------- ------------
3. Full name of person(s) subject Cedar Assets Group Ltd
to the notification obligation:
(iii)
------------------------------------ ----------------------------------------
4. Full name of shareholder(s) (if
different from 3.):(iv)
------------------------------------ ----------------------------------------
5. Date of the transaction and date 23 June 2011
on which the threshold is crossed
or reached: (v)
------------------------------------ ----------------------------------------
6. Date on which issuer notified: 23 June 2011
------------------------------------ ----------------------------------------
7. Threshold(s) that is/are crossed Previously below 3% - 25%
or reached: (vi, vii)
------------------------------------ ----------------------------------------



8. Notified details:
----------------------------------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares (viii, ix)
----------------------------------------------------------------------------------------------------------------------------------------
Class/type of
shares Situation previous
if possible using to the triggering
the ISIN CODE transaction Resulting situation after the triggering transaction
------------------- ------------------------------ -----------------------------------------------------------------------------------
Number
Number of
of Voting Number Number of voting
Shares Rights of shares rights % of voting rights (x)
----------- ------ --------------- ------------- --------------- ------------------------------- ---------------------------------
Indirect
Direct Direct (xi) (xii) Direct Indirect
----------- ------ --- ------- --- ----- --------------- ------------------ ----------- ------------------ -------------
GB00B1GDWB47 0 4,158,233 4,158,233 25.29%

B: Qualifying Financial Instruments
----------------------------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------------------------
Number of voting rights that may be
Type of financial Expiration Exercise / Conversion Period acquired if the instrument is % of voting
instrument date (xiii) (xiv) exercised/ converted. rights
---------------------- --------------- -------------------------------- ------------------------------------- ----------------------

C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments (xv, xvi)
----------------------------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------------------------
Number of
Type of voting rights
financial Exercise Expiration Exercise/ instrument
instrument price date (xvii) Conversion period (xviii) refers to % of voting rights (xix, xx)
----------- -------------- --------------- ---------------------------------------- --------------- -------------------------------
Nominal Delta
----------- -------------- --------------- ---------------------------------------- --------------- -------------------- ---------


Total (A+B+C)
----------------------------------------------------------------------------------------------------------------------------------------
Number of voting rights Percentage of voting rights
----------------------------------------------------------- ---------------------------------------------------------------------------
4,158,233 25.29%
----------------------------------------------------------- ---------------------------------------------------------------------------



9. Chain of controlled undertakings through which
the voting rights and/or the financial instruments
are effectively held, if applicable: (xxi)
----------------------------------------------------------------------------
Not applicable
Proxy Voting:
----------------------------------------------------------------------------
10. Name of the proxy holder:
----------------------------------------------------- ---------------------
11. Number of voting rights proxy holder will cease
to hold:
----------------------------------------------------- ---------------------
12. Date on which proxy holder will cease to hold
voting rights:
----------------------------------------------------- ---------------------
13. Additional information:
----------------------------------------------------- ---------------------
14. Contact name: Michelle Clark
----------------------------------------------------- ---------------------
15. Contact telephone number: [phone]
----------------------------------------------------- ---------------------

[philmar089] 24/6/2011 08:49

only 12.73 million shares market cap £300k nice any one know anything about them

[olly2] 24/6/2011 08:41

does'nt seem to take much to move this.good few buys early on.was watching this yesterday.

[double6] 24/6/2011 08:08

Interesting.

[induna123] 24/5/2011 08:19

Is the market cap only £300k?

[induna123] 24/5/2011 08:05

Some good news out.

RNS Number : 1110H

Ipso Ventures PLC

24 May 2011

Embargoed for release at 07.00 hours 24 May 2011

IPSO VENTURES PLC

("IPSO" or the "Company")

CAMBRIDGE MEDITECH SIGNS AGREEMENT WITH LANTOR (UK)

IPSO Ventures plc (AIM: IPS), the technology commercialisation business, is pleased to announce that its wholly-owned subsidiary, Cambridge Meditech Limited ("Cambridge Meditech"), has signed an agreement with Lantor (UK) Limited ("Lantor") that will lead to the development of advanced wound healing products that are capable of detecting infection in wounds.

The novel, patented technology owned by Cambridge Meditech detects breaches in the body's natural immune system by measuring the presence and concentration of lysozyme in a wound. The advantages of this technology are that it is simple and robust, pathogen independent and only activates once the body's natural immune system has been breached.

The agreement gives Lantor access to the technology for an initial evaluation period of 12 months, with the option for a commercial licence at the end of this period. Should this option be exercised by Lantor, Cambridge Meditech will receive regular milestone payments and royalties from product sales.

Nick Rodgers, CEO of IPSO, said: "We are very excited to work with Lantor on the development of such a novel product. This is yet another example of how, by bringing together know-how and IP from various sources, we are able to develop technologies which are commercially relevant and address serious commercial needs."

[ihavenoclue] 27/3/2011 09:27

Yup ... good job I never bought

[pugugly] 25/3/2011 10:59

Looks like the end of the line. Yet another example of the failure of the British to capitalise on University research OR over optimistic views as to what the IP can generate.

There must be some lessons to be learnt here, because unless UK plc learns how to exploit our fundamental reseach we will end as straw chewing attendents in the Euro theme park for Asian tourists.

[traidemark] 25/3/2011 08:00

rns, theres your answer

NO !!

[ihavenoclue] 24/2/2011 11:06

I am just wondering if it is worth buying at this level ... hmmm

[induna123] 21/2/2011 20:21

They've sold 1.2m in the past month. Still 4.4m left. It's probably not safe to enter until we know whether they've finished selling or not.

[jon12345] 16/2/2011 20:35

Is there a pulse nurse? RAB have murdered it.

[double6] 25/1/2011 08:12

Still bouncing around.

[pugugly] 24/1/2011 11:16

markt:> Good analysis. Agreed looks very bad unless all participating staff cut their remuneration and also overheads.